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Reappraisal of the Immunogenicity and Safety of Three Hepatitis 
A Vaccines in Adolescents
Although the overall incidence of hepatitis A in Korea has been decreasing, adolescents 
remain highly vulnerable to its outbreaks. This study was conducted to compare the 
immunogenicity and safety of three hepatitis A vaccines in Korean adolescents. Healthy 
anti-hepatitis A virus seronegative subjects aged 13 to 19 yr were randomized in three 
equal groups to receive two doses of AvaximTM, Epaxal®, or Havrix®, 6 to 12 months apart. 
Seroconversion rates one month after the first dose were 98%, 95%, and 93% for 
AvaximTM, Epaxal®, and Havrix®, respectively. Seroconversion rates reached 100% for all 
vaccine groups one month after the second dose. Anti-HAV geometric mean 
concentrations (GMCs) were 7,207.7 mIU/mL (95% CI, 6023.1-8684.7), 1,750.5 mIU/mL 
(95% CI, 1362.9-2248.3), and 1,953.5 mIU/mL (95% CI, 1459.4-2614.7) after two doses 
of AvaximTM, Epaxal®, and Havrix® respectively. AvaximTM was significantly more 
immunogenic than Epaxal® and Havrix®, whereas there were no significant differences in 
antibody responses between Epaxal® and Havrix®. Local and systemic solicited adverse 
events (AEs) were mostly of mild-to-moderate intensity and resolved within 5 days. No 
serious AEs were reported. In conclusion, all three vaccines are highly immunogenic and 
well-tolerated in Korean adolescents. (Clinical Trial Registry NCT00483470)
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INTRODUCTION
Hepatitis A virus (HAV) is one of the most common causes of 
acute hepatitis in the world, with 1.5 million cases each year (1). 
The disease prevalence of HAV is closely related to socioeco-
nomic status and sanitation (1-3). Socioeconomic improve-
ments and better sanitation have resulted in fewer children 
with long-term immunity through early-life exposure to non-
immune status (4,5). High-income regions of the world, includ-
ing the Republic of Korea, have very low HAV endemicity levels 
and a high proportion of susceptible adolescents and adults (6). 
In Korea, the seroprevalence of anti-HAV antibody, a marker of 
endemicity, was 11.7%-13.0% in individuals 15-29 yr of age, 
which have resulted in several outbreaks of hepatitis A among 
this age group (3,7-9). Since HAV infection is usually asymp-
tomatic in young children and the likelihood and severity of 
symptoms tends to increase with age from the late teens to twen-
ties (1-5,7,8), prevention through vaccination programs is im-
portant for HAV control in these regions. 
 The first inactivated hepatitis A vaccine (HepA) was devel-
oped in 1992 (10) and there are currently several inactivated 
vaccines available worldwide, including Vaqta® (Merck & Co. 
Inc., West Point, PA, USA), Havrix® (GSK Biologicals, Rixensart, 
Belgium), AvaximTM (Sanofi Pasteur, Lyon, France), and Epaxal® 
(Crucell Vaccines Inc., Leiden, the Netherlands) (2,4,11). All of 
these vaccines have similar properties, are well-tolerated, are 
highly immunogenic, and offer effective protection (2,12,13). 
However, to the best of our knowledge, there have been no com-
parative studies on the immunogenicity and safety of more than 
two types of HepAs. This study was performed to compare the 
immunogenicity of three different types of HepAs in adolescents 
with the recommended two-dose program. In addition, the per-
sistence of immunogenicity prior to the second vaccination and 
the safety profiles of the vaccines were studied.
 
MATERIALS AND METHODS
Study design and participants 
A comparative, open-label, randomized trial (NCT00483470) 
was conducted from May 2012 to October 2013 at Ewha Wom-
ans University Mokdong Hospital in Seoul, Korea. Healthy ado-
lescents 13 to 19 yr of age were considered for inclusion. Partici-
pants were excluded if they met any of the following criteria: 
seropositive for anti-HAV antibodies; hypersensitivity to any 
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vaccine component; previous vaccination with HepA; throm-
bocytopenia or other coagulation disorder; known or suspect-
ed immunological impairment; the administration of immu-
noglobulin or other blood products within 3-11 months, or the 
administration of immunosuppressive therapy within 30 days; 
a history of anaphylactic reaction to any vaccine; a history of a 
previous HAV infection; a current febrile illness (axillary tem-
perature > 37.5°C) or other acute illnesses. 
 Participants were randomly assigned to 1 of 3 treatment groups 
following a randomization sequence created using Stata 10.0 
(StataCorp, College Station, TX, USA) statistical software with a 
1:1:1 allocation using random block sizes of 3, 6, and 9.
 Blood samples for anti-HAV antibody were obtained at each 
visit: enrollment (visit 1), one month after the first dose (visit 2), 
just prior to the second dose (6 to 12 months after the first dose; 
visit 3), and one month following the second dose (visit 4). Se-
rum samples were stored at -70°C until analyzed.
Vaccines and vaccination
AvaximTM is a formaldehyde-inactivated liquid HepA adsorbed 
onto aluminum hydroxide (14). AvaximTM 80U (AvaximTM 80U 
pediatric) is designed for children aged 12 months to 15 yr while 
AvaximTM 160U is designed for those above the age of 16 yr. Ep-
axal® is a formalin-inactivated liquid vaccine, which is attached 
to the virosomes (15,16). Epaxal® 0.25 mL (Epaxal® junior) is for 
children aged 12 months to 16 yr and Epaxal® 0.5 mL is for those 
above 17 yr of age. Havrix® is formaldehyde-inactivated liquid 
vaccine adsorbed onto aluminum hydroxide (10). Havrix® 720 
(Havrix junior) is for children aged 12 months to 18 yr and Ha-
vrix® 1440 is for those above 19 yr of age. All vaccines were stored 
at 2 to 8°C until the time of vaccination.
 Subjects were randomized to receive equal amounts of one 
of the three vaccine groups (Fig. 1). Each group received two 
doses of AvaximTM (Vaccine A), Epaxal® (Vaccine B), or Havrix® 
(Vaccine C) 6 to 12 months apart (The mean duration of the in-
Randomized
n = 157
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1 lost to  
follow-up
Visit 1
(n = 142)
Visit 2
(n = 141)
Visit 3
(n = 138)
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(n = 136)
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safety set
After the first 
dose, n = 51
After the second 
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After the first 
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After the second 
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After the second 
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P/A, n = 9
A/A, n = 8)
n = 43
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Fig. 1. Study design and disposition of subjects. *Subjects were excluded due to ineligibility for the study. ITT, intention-to-treat; PP, per-protocol; P, pediatric dose; A, adult 
dose.
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terval between the first and second dose was 11.7 ± 1.0 months). 
Subjects received either a pediatric dose (AvaximTM 80U, Epax-
al® 0.25, or Havrix® 720) or an adult dose (AvaximTM 160U, Ep-
axal® 0.5 mL, or Havrix® 1440) according to their age. The vac-
cines were administered by intramuscular injection into the 
deltoid muscle. 
Immunogenicity assessment
Total serum anti-HAV antibody levels were determined using 
an electrochemiluminescence immunoassay (Cobas 8000 e602, 
Roche, Mannheim, Germany) in the Seegene Medical Founda-
tion, Seoul, Korea. The detection limit of quantification was 3-60 
mIU/mL. Antibody levels > 60 mIU/mL were tested again after 
appropriate dilution of the serum with phosphate buffered sa-
line (PBS). 
 Seroconversion (or “seroprotection”) was defined as achiev-
ing an anti-HAV antibody titer ≥ 20 mIU/mL after vaccination 
(5,17). The seroconversion rates of the three vaccine groups at 
each visit were studied. The geometric mean concentrations 
(GMCs) of anti-HAV antibody after vaccination were compared 
between the three vaccine groups. GMCs were also compared 
in the pediatric and adult dose subgroups, who received 2 dos-
es of the vaccines in pediatric and adult doses, respectively.
Reactogenicity and safety assessment
All parents/guardians were provided with a digital thermome-
ter and a diary card containing a list of adverse events and their 
grades, as well as instructions for recording concomitant medi-
cations, the use of any antipyretic agents, axillary temperatures, 
and details of local and systemic reactions/symptoms that might 
occur during the 5 days following each vaccination. Each sub-
ject was observed for a period of 30 min after vaccination to de-
tect any immediate local and/or systemic reactions. Local (pain, 
redness, swelling at the injection site) and systemic (fever, head-
ache, dizziness, myalgia, gastrointestinal disorders, poor oral 
intake, and irritability) events were recorded by parents/guard-
ians on the diary cards for 5 days (Days 0-4) following each vac-
cine dose. Unsolicited adverse events (AEs) for one month (Days 
0-30) following each vaccination as well as serious adverse events 
(SAEs) throughout the study periods were monitored. 
 The intensity of each symptom was graded on a scale from 0 
to 3, (“0” signifies no symptoms; ”1” signifies mild symptoms, 
without trouble in daily activities; “2” signifies moderate symp-
toms, with some trouble in daily activities; and “3” signifies se-
vere symptoms, with symptoms preventing normal daily activi-
ty). Injection site reactions were considered related to the vac-
cination, while the causal relationship between all other AEs 
and the vaccination were assessed by investigators based on 
clinical judgment. 
Statistical analysis
The immunogenicity analysis was per-protocol (PP) and only 
included participants who completed the study vaccine admin-
istration and blood collections as scheduled. The safety analysis 
was modified intention-to-treat (ITT) and included all subjects 
with at least one dose of vaccine for which safety data were avail-
able. A sample size of 50 subjects from each group was needed 
to estimate the seroconversion rate following the first dose of 
each vaccine with 95% confidence within a margin of error of 
8% (based on the assumption of an estimated rate of 92% sero-
conversion). Antibody responses were assessed by calculating 
the GMCs with a 95% CI and seroconversion rates at visits 2, 3, 
and 4. Serum samples with total HAV antibody levels < 3 mIU/
mL were assigned a value of 1.5 mIU/mL for analysis purposes. 
The GMCs of each vaccine group at each visit were compared 
using analysis of variance (ANOVA) with the Bonferroni correc-
tion or the Student t-test. Differences in the proportions of pa-
tients with adverse events were compared using a chi-square 
test or Fisher’s exact test with the Bonferroni adjustment. Re-
verse cumulative distribution curves (RCDCs) for anti-HAV an-
tibody concentrations were constructed to illustrate the immune 
responses in the three vaccine groups at each visit. Statistical 
analysis was conducted using SPSS statistical software (version 
18.0; SPSS Inc., Chicago, IL, USA).
Ethics statement
The study protocol was reviewed and approved by the institu-
tional review board of the Ewha Womans University Mokdong 
Hospital (IRB No. 12-07B-07). The study was conducted in ac-
cordance with good clinical practices (national regulations and 
ICH E6) and the principles of the Helsinki Declaration. Written 
and informed consent was obtained from all subjects and their 
parents/legal guardians following a detailed explanation of the 
study.
 
RESULTS
Study population
A total of 157 participants were randomized into three groups 
(53 in the Vaccine A [AvaximTM] group, 52 in the Vaccine B [Ep-
axal®] group, and 52 in the Vaccine C [Havrix®] group). The de-
mographic characteristics of the subjects in each group are 
shown in Table 1. Among the total participants, 15 were exclud-
ed due to study ineligibility. A total of 136 subjects were in the 
population evaluated for immunogenicity (50 in the Vaccine A 
group [17 pediatric/pediatric dose recipients, 9 pediatric/adult 
dose recipients, and 24 adult/adult dose recipients], 43 in the 
Vaccine B group [26 pediatric/pediatric dose recipients, 9 pedi-
atric/adult dose recipients, and 8 adult/adult dose recipients], 
and 43 in the Vaccine C group [39 pediatric/pediatric dose re-
cipients, 4 pediatric/adult dose recipients]) (Fig. 1). A total of 
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Table 1. Demographic characteristics of the study population
Characteristics
Vaccine A 
(n = 53)
Vaccine B 
(n = 52)
Vaccine C 
(n = 52)
P value
Total subjects
Gender, No. (%)
   Male 32 (64.2) 30 (57.7) 26 (61.5) NS
   Female 19 (35.8) 22 (42.3) 17 (38.5)
Age (yr)
   Mean 16.2 15.8 16.1 NS
   Median 16.2 15.6 16.4
   Range 13.2-19.9 13.0-19.7 13.0-18.8
Subgroups according to vaccine dose
Age (yr)
   Pediatric dose n = 17 n = 26  n = 39
      Mean 14.2 14.7 16.0
      Median 14.1 14.8 16.2
      Range 13.2-14.8 13.0-15.9 13.0-18.0
   Adult dose n = 24 n = 8 -
      Mean 17.4 18.3 -
      Median 17.1 18.2 -
      Range 16.1-19.6 17.5-19.7 -
NS, not significant.
Table 2. Anti-HAV GMC levels and seroconversion rates of the three vaccines at each visit (per-protocol subjects) 
Parameters Vaccine A (n = 50) Vaccine B (n = 43) Vaccine C (n = 43)
Visit 1*
   GMC (95% CI) (mIU/mL)
   Seroprotection rate (%)
4.3 (3.4-5.2)
0
4.1 (3.4-5.2)
0
4.2 (3.3-5.2)
0
Visit 2
   GMC (95% CI) (mIU/mL)
   Seroprotection rate (%)
735.5 (563.5-1,024.4)
98
245.7 (184.3-357.7)
95
192.9 (129.6-287.0)
93
Visit 3
   GMC (95% CI) (mIU/mL)
   Seroprotection rate (%)
277.0 (238.9-322.6)
100
195.9 (167.4-222.6)
100
183.9 (168.7-200.5)
100
Visit 4
   GMC (95% CI) (mIU/mL)
   Seroprotection rate (%)
7,207.7 (6,023.1-8,684.7)
100
1,750.5 (1,362.9-2,248.3)
100
1,953.5 (1,459.4-2,614.7)
100
*Visit 1, at enrollment; visit 2, one month after the first dose; visit 3, just prior to the second dose (6 to 12 months after the first dose); visit 4, one month following the second 
dose. GMC, Anti-HAV antibody geometric mean concentration.
141 subjects (51 in the Vaccine A group, 47 in the Vaccine B group, 
and 44 in the Vaccine C group) were included in the safety pop-
ulation for the first vaccination, 138 subjects (50 in the Vaccine 
A group, 45 in the Vaccine B group, and 43 in the Vaccine C 
group) were included in the safety population for the second 
vaccination. 
Immunogenicity
The anti-HAV GMC levels and seroconversion rates of the three 
groups at each visit are summarized in Table 2. At visit 2 (one 
month after the first dose of vaccine), the seroconversion rates 
of the Vaccine A, Vaccine B, and Vaccine C groups were 98%, 
95%, and 93%, respectively, differences that were not statistical-
ly significant. At visit 3 (6 to 12 months after the first dose), all 
subjects in all three groups showed 100% seroprotection, which 
was maintained to visit 4 (one month after the second dose of 
vaccine). 
 Fig. 2 shows a comparison of the immunogenicity of the three 
Fig. 2. Comparison of the immunogenicity of the three hepatitis A vaccines at each visit. (A) Comparison among the Vaccine A, Vaccine B, and Vaccine C groups. (B) Compari-
son among the subgroups with three pediatric doses of each vaccine. (C) Comparison between the subgroups with two adult doses of each vaccine. Visit 1, at enrollment; visit 2, 
one month after the first dose; visit 3, just prior to the second dose (6 to 12 months after the first dose); visit 4, one month following the second dose.
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HepAs at each visit. At visits 2, 3, and 4, anti-HAV GMCs were 
significantly higher in the Vaccine A group than in the Vaccine 
B group (visits 2, 3, and 4: P < 0.001, P = 0.001, and P <  0.001, 
respectively) and the Vaccine C groups (visits 2, 3, and 4: P < 0.001, 
P < 0.001, and P < 0.001, respectively). In the pediatric dose 
subgroups, anti-HAV GMCs were also significantly higher in 
the Vaccine A subgroup than in the other subgroups at Visit 2 
(Vaccine A subgroup vs. Vaccine B subgroup: P = 0.018, Vac-
cine A subgroup vs. Vaccine C subgroup: P = 0.003) and Visit 4 
(Vaccine A subgroup vs. Vaccine B subgroup: P < 0.001, Vaccine 
A subgroup vs. Vaccine C subgroup: P < 0.001). In the adult dose 
subgroups, anti-HAV GMC was significantly higher in the Vac-
cine A subgroup than in the Vaccine B subgroup at Visit 4 (P =  
0.001). Analyses in the adult dose subgroups were performed 
only between the Vaccine A and Vaccine B subgroups since there 
were no subjects who received 2 adult doses of vaccine in the 
Vaccine C group. 
 The RCDCs in Fig. 3 show that the curves after the first and 
Fig. 3. Reverse cumulative distribution curves of the anti-HAV 
antibody concentrations for the three vaccine groups at each 
visit. Vertical solid line, cut-off value for anti-HAV seroprotec-
tion, 20 mIU/mL.
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Table 3. Local and systemic adverse events (AEs) after vaccination (Intention-to-treat protocol subjects)
No. (%) of subjects with reactions
First injection Second injection
Vaccine A (n = 51) Vaccine B (n = 47) Vaccine C (n = 44) Vaccine A (n = 50) Vaccine B (n = 45) Vaccine C (n = 43)
Local reactions
   Pain
   Redness
   Swelling
   Any*
11 (22)
5 (10)
1 (4)
14 (27)
12 (26)
8 (17)
4 (9)
18 (38)
13 (30)
5 (9)
0 (0)
17 (39)
9 (18)
1 (2)†
0 (0)‡
9 (18)
14 (31)
9 (20)
6 (13)
18 (40)
7 (16)
6 (14)
3 (7)
12 (28)
Systemic reactions
   Fever
   Headache
   Dizziness
   Myalgia
   GI disorders
   Poor oral intake
   Irritability
   Any*
0 (0)
2 (4)
0 (0)
1 (2)
1 (2)
0 (0)
0 (0)
4 (9)
0 (0)
2 (4)
0 (0)
1 (2)
0 (0)
0 (0)
0 (0)
3 (6)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
1 (2)
0 (0)
0 (0)
0 (0)
0 (0)
1 (2)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
*Any of the above local or systemic reactions; †Vaccine A vs. Vaccine B P = 0.018; ‡Vaccine A vs. Vaccine B P = 0.027.
second doses of vaccination shifted to the right compared to 
those before each vaccination in all three vaccine groups. This 
distribution indicated that the anti-HAV concentration increased 
with repeated vaccination.
Reactogenicity and safety 
No subjects in any of the groups had immediate AEs in the 30 
min after vaccination or vaccine-related SAEs after each vacci-
nation. Local and systemic AEs after immunization are shown 
in Table 3. The three vaccines were well-tolerated, with a similar 
incidence and type of post-vaccination reactions, with the ex-
ception of a higher frequency of redness and swelling after the 
second injection (P = 0.018 and P = 0.027, respectively) in the 
Vaccine B group as compared with the Vaccine A group. Pain 
was the most common AE in all vaccine groups. Local and sys-
temic AEs were mostly mild-to-moderate in intensity and re-
solved within 5 days. All reported AEs resolved without compli-
cations and there were no study withdrawals due to adverse 
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events or deaths during the study period. 
 
DISCUSSION
This study demonstrated that the three HepAs showed good 
immunogenic responses and were well-tolerated in adolescents, 
but that there may be different quantitative immune responses 
depending on the type of vaccine. To the best of our knowledge, 
this is the first study comparing the immunogenicity and safety 
of three types of HepAs. Previous studies (4,16,18-21), which 
mostly compared two vaccine groups, reported that the vac-
cines that were studied were immunogenic and safe. In accor-
dance with previous studies, our results showed that the sero-
protection rates were ≥ 90% one month after the first dose and 
100% after the second dose in all vaccine groups. Moreover, the 
seroprotective antibody levels were maintained throughout the 
study period.
 Despite good immunogenic responses in all study vaccines, 
there seemed to be kinetic differences in antibody production 
after vaccination based on the type of vaccine. In our results, 
anti-HAV GMCs were significantly higher in the AvaximTM group 
than in the other two groups at all visits after vaccination. Simi-
lar tendencies were also noted in the GMCs of both the pediat-
ric and adult dose subgroups. These results are in agreement 
with those of previous studies (22,23), which reported that the 
antibody concentrations in response to AvaximTM were higher 
than with other target vaccines. Conflicting results have been 
reported in several studies that have compared the immunoge-
nicity of Epaxal® and Havrix® in children. Epaxal® 0.25 showed 
superior immunogenicity than Havrix® 720 in some studies (24, 
25), although the converse has been demonstrated in other stud-
ies (16). In our study, the anti-HAV GMCs of the Epaxal® and 
Havrix® vaccine groups (both the overall group and the pediat-
ric dose subgroup) were comparable, with no statistical differ-
ences. Unfortunately, there have been few studies that have com-
pared the immunogenicity between AvaximTM and Epaxal® in 
either pediatric or adult doses; hence it was difficult to compare 
our results with those of previous studies.
 With respect to safety, all three vaccines showed very good 
safety in the present study. Solicited local and systemic reac-
tions were mostly mild and transient. Injection site pain was 
the most common symptom, similar to what has been reported 
by other investigators (2,4,16,18). Although redness and swell-
ing at the injection site were reported significantly more fre-
quently in the Epaxal® group as compared with the AvaximTM 
group after the booster vaccination in our study, there were no 
statistically significant differences in the other solicited AEs 
among the three vaccine groups. In previous studies, despite 
subtle differences in the AEs between different vaccines, the 
study vaccines overall were well-tolerated. One previous study 
reported that injection site pain tended to occur more frequent-
ly and with greater intensity in subjects vaccinated with the al-
um-absorbed vaccine (24). However, our results indicated that 
the pain reaction in all vaccines were similar in incidence, with-
out significant differences based on the type of adjuvant. This 
suggests that local reactions, including pain, are not significant-
ly related to the adsorbents in the vaccines.
  In recent seroepidemiologic data of hepatitis A in Korea (7), 
there has been a significant change in the seroprevalence pat-
terns over the past 30 yr. The most susceptible group has shifted 
from children less than 10 yr of age to individuals 10-29 yr of 
age. These changes are related with improvements in hygiene 
and the introduction of HepA. However, these seroprevalence 
patterns also reflect the possibility of disease outbreak in indi-
viduals 10-29 yr of age, so prevention through the vaccination 
of adolescents should be emphasized. Our results support the 
recommendation of administering HepA in adolescents to pre-
vent hepatitis A, which can result in serious morbidity in this 
age group.
 This study has several limitations. First, there were a limited 
number of subjects per study vaccine. Therefore, we should be 
careful in interpreting the results. Second, all of the subjects 
were Korean, so possible racial/ethnic factors in the immune 
response to the vaccines should be considered when interpret-
ing these study results. Despite these shortcomings, our data 
should aid in the understanding of the immunogenicity and 
safety of HepAs in adolescents.
 In conclusion, the three HepAs studied were highly immu-
nogenic and well-tolerated in adolescents, although there may 
be differences in the kinetics of antibody production after im-
munization depending on the type of vaccine used. Thus, they 
can be recommended for routine vaccination in countries with 
a high proportion of susceptible adolescents, including Korea.
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